NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,413.79 +206.66 (+1.14%) CRUDE OIL
79.21 +0.26 (+0.33%) GOLD FUTURES
2,311.10 +1.50 (+0.06%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,510.59 +1,682.04 (+3.67%)
Cryo-Cell International, Inc. (CCEL)
| Previous close | 8.29 |
| Open | 8.30 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1300 |
| Day's range | 8.26 - 8.59 |
| 52-week range | 3.67 - 8.67 |
| Volume | |
| Avg. volume | 11,308 |
| Market cap | 69.455M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.16 |
| Earnings date | 12 Jul 2024 - 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 01 Sept 2022 |
| 1y target est | 9.00 |
Business WireCord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results
OLDSMAR, Fla., April 15, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024.
Business WireCryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value
OLDSMAR, Fla., March 25, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company" or "Cryo-Cell"), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or de
Business WireCryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023
OLDSMAR, Fla., February 28, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2023.
